136 patents currently held
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
38
Ending by 2030
Jan 2027
Next term end
109
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2030 · High confidence
Also notable
Ends Mar 2032 · High confidence
Also notable
Ends Dec 2028 · High confidence
Also notable
Ends Jul 2029 · High confidence
Also notable
Ends May 2035 · High confidence
Also notable
Ends Apr 2035 · High confidence
Also notable
Ends Oct 2029 · High confidence
Also notable
Ends Sep 2038 · High confidence
Transdermal Therapeutic System for Administering the Active Substance Buprenorphine
US 9,308,202
The most cited patent in this portfolio, cited by 84 later US patents, top 5% of utility patents granted in 2016 in our data. Protection runs to 2030.
Polyvinylpyrrolidone for the Stabilization of a Solid Dispersion of the Non-Crystalline Form of Rotigotine
US 9,925,150
Cited by 13 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Transdermal Therapeutic System Comprising an Adhesive Layer Method for Siliconizing the Back Layer or the System and Use of Said Back Layer
US 9,226,903
Cited by 25 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2028.
Transdermal Pharmaceutical Preparation Containing Active Substance Combinations, for Treating Parkinson's Disease
US 8,980,308
Cited by 52 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Transdermal Delivery System Containing Rotigotine
US 11,633,367
Cited by 5 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2035.
System for the Transdermal Delivery of Active Ingredient
US 10,485,967
Granted 2019. Computed term ends 2035.
Medical Active Substance Patch with Reduced Optical Conspicuousness on the Skin
US 10,653,636
Granted 2020. Computed term ends 2029.
Iontophoretic Microneedle Device
US 11,534,589
Granted 2022. Computed term ends 2038.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 21, 2026The maintenance fee for Transdermal Therapeutic System Comprising Active Ingredient Particles and Having Increased Active Ingredient Flux (US 10,292,942) comes due Nov 21, 2026. Unpaid by May 21, 2027, it lapses early.
- 3 fees due Dec 11 to 30, 2026 · next Dec 11
- 5 fees due Jan 2 to 30, 2027 · next Jan 2
- 6 fees due Mar 3 to 29, 2027 · next Mar 3
- 1 fee due Apr 30, 2027The maintenance fee for Device and Method for Producing Sealed-Edge Pouches (US 11,801,986) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
- 3 fees due May 10 to 26, 2027 · next May 10
- 2 fees due Jun 15 to 29, 2027 · next Jun 15
- 1 fee due Jul 5, 2027The maintenance fee for Transdermal Therapeutic System Comprising an Adhesive Layer Method for Siliconizing the Back Layer or the System and Use of Said Back Layer (US 9,226,903) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
- 1 fee due Aug 23, 2027The maintenance fee for Method of Using a Film-Shaped Preparation Comprising Oily Substances for Oral Administration (US 9,265,779) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
- 1 fee due Sep 12, 2027The maintenance fee for Method of Marking Film-Like Dosage Forms (US 11,925,711) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 3 fees due Oct 12 to 26, 2027 · next Oct 12
- 1 fee due Nov 19, 2027The maintenance fee for Medical Active Substance Patch with Reduced Optical Conspicuousness on the Skin (US 10,653,636) comes due Nov 19, 2027. Unpaid by May 19, 2028, it lapses early.
Recent changes
- 6 of the patents on this record were granted since Aug 23, 2026
- 1 term has ended since Aug 23, 2026
- Oct 11 US 11,464,760 Frigostable Composition for Iontophoretic Transdermal Delivery of a Triptan Compound · lapsed on the fee record
What they patent
The largest of its 109 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,568,845 | Transdermal therapeutic system with fentanyl or related substances In force · High confidence | In force | High confidence | |
| US 10,596,126 | Transdermal Therapeutic System Comprising Active Ingredient Particles and Having Increased Active Ingredient Flux In force · High confidence | In force | High confidence | |
| US 9,421,174 | Transdermal Therapeutic System with High Rate of Utilization of Active Substance and Dosing Accuracy In force · High confidence | In force | High confidence | |
| US 9,717,698 | Transdermal Therapeutic System with High Rate of Utilization of Active Substance and Dosing Accuracy In force · High confidence | In force | High confidence | |
| US 9,211,991 | Packaging for Active Substance-Containing Films and Method for Producing Them In force · High confidence | In force | High confidence | |
| US 8,075,912 | Autodestructive Transdermal Therapeutic System In force · High confidence | In force | High confidence | |
| US 11,612,571 | Transdermal Therapeutic System for Administering Water-Soluble Peptides and Polypeptides In force · High confidence | In force | High confidence | |
| US 10,039,711 | Self-Adhesive Film for Teeth In force · High confidence | In force | High confidence | |
| US 9,226,903 | Transdermal Therapeutic System Comprising an Adhesive Layer Method for Siliconizing the Back Layer or the System and Use of Said Back Layer In force · High confidence | In force | High confidence | |
| US 8,894,621 | Self-destructing transdermal therapeutic system having improved functionality and efficacy In force · High confidence | In force | High confidence |
Also on record, not counted in the 136: 8 patents in force now held by others · 148 patents ended · 70 applications pending · 170 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.